1 min read.Updated: 05 May 2021, 12:49 AM ISTLeroy Leo
The Ahmedabad-based drugmaker had started the 28,000-participant phase 3 trial of its DNA plasmid vaccine in February
Drugmaker Zydus Cadila is expecting the first set of its interim efficacy data for its covid-19 vaccine this month, following which the company will immediately apply for an emergency use authorization with the Indian regulator, managing director Sharvil Patel said.
Recommended For You
Select your Category
Internet Not Available
Wait for it…
Log in to our website to save your bookmarks. It'll just take a moment.